US Pharma MarketingThe post Countable Labs raises $26m for PCR technology advancement appeared first on Medical Device Network.
Countable Labs raises $26m for PCR technology advancement
Countable Labs claims that its Countable PCR technology is “at least 10 times” more sensitive than conventional PCR. Countable Labs claims that its Countable PCR technology is “at least 10 times” more sensitive than conventional PCR. Countable Labs’ lead product, Countable PCR, is designed for application in areas including minimal residual disease (MRD) testing, cell and gene therapy (CGT), and biomarker validation. Credit: rathshiki / Shutterstock.com Countable Labs has raised $26m to advance the development and commercialisation activities for its single-molecule polymerase chain reaction (PCR) technology. The California-based company’s financing round was led by ARCH Venture Partners, with additional participation…
Countable Labs claims that its Countable PCR technology is “at least 10 times” more sensitive than conventional PCR.
Source: Medical Device Network